Five Prime Therapeutics, Inc. Deferred Tax Assets, Net of Valuation Allowance
Five Prime Therapeutics, Inc. had Deferred Tax Assets, Net of Valuation Allowance of $5.72 million as of 2020-12-31, per its 10-K filed 2021-03-22.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsNet · last filed 2021-03-22
- 2020-12-31: Deferred Tax Assets, Net of Valuation Allowance $5.72M.
- 2019-12-31: Deferred Tax Assets, Net of Valuation Allowance $9.43M.
- 2018-12-31: Deferred Tax Assets, Net of Valuation Allowance $3.85M.
- 2017-12-31: Deferred Tax Assets, Net of Valuation Allowance $4.51M; Deferred Tax Assets, Net of Valuation Allowance as first filed $3.18M.
| Period end | Deferred Tax Assets, Net of Valuation Allowance | Deferred Tax Assets, Net of Valuation Allowance as first filed |
|---|---|---|
| 2020-12-31 | $5.72M 10-K · filed 2021-03-22 | |
| 2019-12-31 | $9.43M 10-K · filed 2021-03-22 | |
| 2018-12-31 | $3.85M 10-K · filed 2020-02-27 | |
| 2017-12-31 | $4.51M 10-K · filed 2019-02-26 | $3.18M 10-K · filed 2018-02-27 |
| 2016-12-31 | $0.00 10-K · filed 2018-02-27 |